Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1611367 | 0.80 | GAA (0.42) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1610935 | 0.79 | MAPT (0.44) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1610099 | 0.79 | MAPT (0.44) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL1610558 | 0.75 | GAA (0.43) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL304242 | 0.73 | CHAT (0.50) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| Phenanthrene SCHEMBL29016443 | 0.73 | ALDH1A1 (0.63) | GAATDP1L3MBTL1TLR8ALDH1A1 | |
| SCHEMBL303905 | 0.72 | CHAT (0.52) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL303704 | 0.72 | CHAT (0.52) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL302934 | 0.72 | CHAT (0.52) | GAATDP1L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL304715 | 0.72 | CHAT (0.52) | GAATDP1L3MBTL1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377315-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2024-04-18 | — | — | US | disclosed |
| WO-2024076614-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024030908-A1 | MULTI-CYCLIC IRAK1 AND IRAK4 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023250431-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023245123-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4267142-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4262802-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| WO-2011126903-A2 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003082263-A1 | SULFAMIC ACIDS AS INHIBITORS OF HUMAN CYTOPLASMIC PROTEIN TYROSINE PHOSPHATASES | ONTOGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2000033836-A9 | 5-MEMBERED HETEROCYCLES FOR THE TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF SELECTINS | ONTOGEN CORP (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000033836-A1 | 5-MEMBERED HETEROCYCLES FOR THE TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF SELECTINS | ONTOGEN CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034255-A1 | SUBSTITUTED THIAZOLES FOR TREATMENT OF HUMAN DISEASES INVOLVING MODULATORS OF P-, L- AND E- SELECTIN | ONTOGEN CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124468-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK2 | GAA 1982/4885TDP1 950/4885L3MBTL1 938/4885 |
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | GAA 1830/4885TDP1 735/4885L3MBTL1 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.